
    
      Because State Food and Drug Administration (SFDA) exempted manufacturers from conducting
      clinical trials of Sunitinib in China, overall efficacy and safety data of Sunitinib in
      Chinese patients with renal cell carcinoma were deficiency. The investigators carried out
      this research project will be sufficient evidence, and help clinicians in China to make
      decision in real daily practice.
    
  